Anti-SSTR2 x anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target-dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumors

被引：12
|
作者：
Lee, Sung-Hyung
Chu, Seung Y.
Rashid, Rumana
Phung, Sheryl
Leung, Irene W.
Muchhal, Umesh S.
Moore, Gregory L.
Bernett, Matthew J.
Schubbert, Suzanne
Ardila, Connie
Bonzon, Christine
Foster, Paul
Szymkowski, David E.
Desjarlais, John R.
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-3633
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3633
引用
收藏
页数：2
相关论文
共 33 条
  • [21] EFFECTS OF INVIVO ADMINISTRATION OF ANTI-CD3 MONOCLONAL-ANTIBODY ON T-CELL FUNCTION IN MICE .2. INVIVO ACTIVATION OF T-CELLS
    HIRSCH, R
    GRESS, RE
    PLUZNIK, DH
    ECKHAUS, M
    BLUESTONE, JA
    JOURNAL OF IMMUNOLOGY, 1989, 142 (03): : 737 - 743
  • [22] CD20xCD3 Bispecific Fully Human Antibody Induces Potent Anti-Tumor Activity Against CD20-Expressing Tumors in Immune Competent Mice Humanized for CD20 and CD3
    Varghese, Bindu
    Menon, Jayanthi
    Rodriguez, Luis
    Olson, Kara
    Krueger, Pamela
    Huang, Tammy
    Smith, Eric
    Thurston, Gavin
    Kirshner, Jessica R.
    BLOOD, 2015, 126 (23)
  • [23] Immunotherapy with Anti-CD3 x Anti-CMV Bispecific Antibody (CMVBi) Armed Donor Derived Activated T Cells (ATC) - A Novel Strategy against Cytomegalovirus (CMV) Post Allogeneic Stem Cell Transplantation (SCT).
    Ramesh, Mayur S.
    Thakur, Archana
    Pellett, Philip
    Das, Subhendu
    Al-Kadhimi, Zaid S.
    Lum, Lawrence G.
    BLOOD, 2009, 114 (22) : 475 - 476
  • [24] Fate and function of anti-CD3 activated T cells (ATC) armed with OKT3 x anti-Her2/Neu bispecific antibody (Her2Bi) in patients with Her2/neu+ tumors
    Lum, L
    Grabert, R
    Gall, J
    Kouttab, N
    JOURNAL OF IMMUNOTHERAPY, 2003, 26 (06): : S21 - S21
  • [25] Transfer of Cellular and Humoral Anti-Tumor Immunity with Immune T Cells After Stem Cell Transplant (SCT) for Metastatic Breast Cancer Following "Vaccination" with Anti-CD3 x Anti-Her2/Neu Bispecific Antibody (Her2Bi) Armed Activated T Cells
    Thakur, Archana
    Al-Kadhimi, Zaid
    Pray, Cassara
    Tomaszewski, Elyse N.
    Rathore, Ritesh
    Steele, Patricia A.
    Abidi, Muneer H.
    Ayash, Lois
    Schalk, Dana L.
    Myers, Karen
    Mitchell, Alice
    Deol, Abhinav
    Uberti, Joseph P.
    Ratanatharathorn, Voravit
    Lum, Lawrence G.
    BLOOD, 2011, 118 (21) : 835 - 835
  • [26] ATOR-4066, a Neo-X-Prime bispecific antibody targeting CD40 and CEA, activates myeloid cells in primary human tumors in vitro and induces anti-tumor immunity in vivo
    Hagerbrand, Karin
    Sundstedt, Anette
    Levin, Mattias
    de Coana, Yago Pico
    Varas, Laura
    Ljung, Lill
    Nilsson, Anneli
    Celander, Mona
    Jimenez, David Gomez
    Andersson, Hampus
    Lindstedt, Malin
    Ellmark, Peter
    CANCER RESEARCH, 2023, 83 (07)
  • [27] PRIMED AND BOOSTED ANTI-BREAST CANCER TUMOR IMMUNITY AFTER AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANT (PBSCT): IN VIVO PRIMING WITH T CELLS ARMED WITH ANTI-CD3 X ANTI-HER2/NEU BISPECIFIC ANTIBODY (HER2BI) PRE PBSCT AND BOOSTING AFTER PBSCT WITH ACTIVATED T CELLS (ATC)
    Lum, L. G.
    Thakur, A.
    Al-Kadhimi, Z.
    Abidi, M.
    Ayash, L.
    Cummings, F.
    Rathore, R.
    Uberti, J. P.
    Ratanatharathorn, V
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (02) : S166 - S166
  • [28] Enhanced anti-breast cancer cyotoxicity, after autologous peripheral blood stem cell transplant (PBSCT) by boosting with multiple infusions of activated T cells (ATC) armed with anti-CD3 x anti-Her2 bispecific antibody (Her2Bi) prior to PBSCT
    Lum, Lawrence G.
    Al-Kadhimi, Zaid
    Skuba, Cassara
    Ratanatharathorn, Voravit
    Uberti, Joseph P.
    BLOOD, 2007, 110 (11) : 807A - 808A
  • [29] GENERATION, PROPAGATION, AND TARGETING OF HUMAN CD4+ HELPER KILLER T-CELLS INDUCED BY ANTI-CD3 MONOCLONAL-ANTIBODY PLUS RECOMBINANT IL-2 - AN EFFICIENT STRATEGY FOR ADOPTIVE TUMOR-IMMUNOTHERAPY
    NISHIMURA, T
    NAKAMURA, Y
    TAKEUCHI, Y
    TOKUDA, Y
    IWASAWA, M
    KAWASAKI, A
    OKUMURA, K
    HABU, S
    JOURNAL OF IMMUNOLOGY, 1992, 148 (01): : 285 - 291
  • [30] PD1 X TGFBR2 AND CD5 X TGFBR2 BISPECIFICS SELECTIVELY BLOCK TGFBR2 ON TARGET-POSITIVE T CELLS, PROMOTE T CELL ACTIVATION, AND ELICIT AN ANTI-TUMOR RESPONSE IN SOLID TUMORS
    Moore, Gregory
    Schubbert, Suzanne
    Bonzon, Christine
    Avery, Kendra
    Rashid, Rumana
    Pong, Erik
    Ochyl, Lukasz
    Nisthal, Alex
    Chu, Seung
    Ernst, James
    Desjarlais, John
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A913 - A913
1234